Wed, October 20, 2021
Tue, October 19, 2021
Mon, October 18, 2021
Sun, October 17, 2021
Fri, October 15, 2021
Thu, October 14, 2021
Wed, October 13, 2021
Tue, October 12, 2021
Mon, October 11, 2021

Judah Frommer Maintained (SRPT) at Hold with Decreased Target to $95 on, Oct 15th, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-95-on-oct-15th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Judah Frommer of Credit Suisse, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $100 to $95 on, Oct 15th, 2021.

Judah has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 2 agree with Judah's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021


These are the ratings of the 3 analyists that currently disagree with Judah


  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021